These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 18259679

  • 1. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of osteoblast function in vitro by aminobisphosphonates.
    Orriss IR, Key ML, Colston KW, Arnett TR.
    J Cell Biochem; 2009 Jan 01; 106(1):109-18. PubMed ID: 19003973
    [Abstract] [Full Text] [Related]

  • 3. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 01; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 4. Osteoblast proliferation and maturation by bisphosphonates.
    Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS.
    Biomaterials; 2004 Aug 01; 25(18):4105-15. PubMed ID: 15046901
    [Abstract] [Full Text] [Related]

  • 5. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ.
    Bone; 2008 May 01; 42(5):848-60. PubMed ID: 18325866
    [Abstract] [Full Text] [Related]

  • 6. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec 01; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.
    Cancer Res; 2000 Nov 01; 60(21):6001-7. PubMed ID: 11085520
    [Abstract] [Full Text] [Related]

  • 8. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
    Komatsu K, Shimada A, Shibata T, Wada S, Ideno H, Nakashima K, Amizuka N, Noda M, Nifuji A.
    J Endocrinol; 2013 Nov 01; 219(2):145-58. PubMed ID: 24096963
    [Abstract] [Full Text] [Related]

  • 9. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization.
    Brandao-Burch A, Utting JC, Orriss IR, Arnett TR.
    Calcif Tissue Int; 2005 Sep 01; 77(3):167-74. PubMed ID: 16075362
    [Abstract] [Full Text] [Related]

  • 10. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
    Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD.
    Eur J Pharmacol; 2008 Dec 14; 600(1-3):140-7. PubMed ID: 18973752
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
    Singh US, Shankar R, Kumar A, Trivedi R, Chattopadhyay N, Shakya N, Palne S, Gupta S, Hajela K.
    Bioorg Med Chem; 2008 Sep 15; 16(18):8482-91. PubMed ID: 18752963
    [Abstract] [Full Text] [Related]

  • 12. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
    Idris AI, Greig IR, Bassonga-Landao E, Ralston SH, van 't Hof RJ.
    Endocrinology; 2009 Jan 15; 150(1):5-13. PubMed ID: 18772231
    [Abstract] [Full Text] [Related]

  • 13. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O, Tiedemann K, Komarova SV.
    Bone; 2011 Feb 15; 48(2):202-11. PubMed ID: 20849994
    [Abstract] [Full Text] [Related]

  • 14. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A, Little DG.
    Biochem Biophys Res Commun; 2005 Dec 16; 338(2):710-6. PubMed ID: 16243296
    [Abstract] [Full Text] [Related]

  • 15. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
    Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B.
    J Bone Miner Res; 2003 Jul 16; 18(7):1186-97. PubMed ID: 12854828
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 16; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 18. 2010 Young Investigator Award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization.
    Schoenecker J, Mignemi N, Stutz C, Liu Q, Edwards J, Lynch C, Holt G, Schwartz H, Mencio G, Hamm H.
    Spine (Phila Pa 1976); 2010 Apr 20; 35(9):1008-16. PubMed ID: 20407341
    [Abstract] [Full Text] [Related]

  • 19. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
    Idris AI, Landao-Bassonga E, Ralston SH.
    Bone; 2010 Apr 20; 46(4):1089-99. PubMed ID: 20096813
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 20; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.